News

News 27.09.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present on its lead-212 (212Pb)-labeled Radio-DARPin Therapeutic (RDT) targeting delta-like...

News 25.09.2024 Boehringer Ingelheim said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic diseases in pets. With the acquisition, Boehringer Ingelheim strengthens its animal health research and development (R&D) pipeline, specifically in the fast-growing pet therapeutics category. As life expectancy for...

News 24.09.2024 Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association. The funding from Target ALS and...

News 19.09.2024 September 18, 2024. ZURICH, Switzerland and NEWTON, Massachusetts, US. –GlobeNewswire– Biognosys, a leading inventor and provider of software solutions for mass spectrometry-based proteomics data analysis, today announced the rollout of a Value-added Reselling agreement for Biognosys’ Spectronaut® software with Thermo Fisher Scientific.  The agreement focuses on the co-marketing and co-selling of Biognosys’ Spectronaut software with...

News 18.09.2024 Sep 17, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-inclass therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a Series C financing round of $11 million. The round was led by existing...